See every side of every news story

Published 7 hours ago • loading... • Updated 9 hours ago

BridgeBio Pharma (NASDAQ:BBIO) Posts Earnings Results

Summary by MarketBeat

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analysts' expectations of $293.47 million.

2 Articles

2 Articles

BridgeBio signals 3 launches in next 7 months with BBP-418 November 27 PDUFA and infigratinib February 4, 2027 PDUFA (NASDAQ:BBIO)

BridgeBio Q3 2026 earnings highlight Attruby growth, strong cash, and key FDA catalysts ahead.

9 hours ago·Ra'anana, Israel

Read Full Article

BridgeBio Pharma (NASDAQ:BBIO) Posts Earnings Results

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analysts' expectations of $293.47 million.

13 hours ago·Sioux Falls, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right1Center1Last Updated8 hours agoBias Distribution

50% Center, 50% Right

Bias Distribution

50% of the sources are Center, 50% of the sources lean Right

50% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States 13 hours ago on Thursday, October 29, 2026.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics